Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study

di Giuseppe, Romina; Kühn, Tilman; Hirche, Frank; Buijsse, Brian; Dierkes, Jutta; Fritsche, Andreas; Kaaks, Rudolf; Boeing, Heiner; Stangl, Gabriele I.; Weikert, Cornelia
July 2015
PLoS ONE;7/20/2015, Vol. 10 Issue 7, p1
Academic Journal
Background: Increased fibroblast growth factor 23 (FGF23), a bone-derived hormone involved in the regulation of phosphate and vitamin D metabolism, has been related to the development of cardiovascular disease (CVD) in chronic kidney disease patients and in the general population. However, what determines higher FGF23 levels is still unclear. Also, little is known about the influence of diet on FGF23. The aim of this study was therefore to identify demographic, clinical and dietary correlates of high FGF23 concentrations in the general population. Methods: We performed a cross-sectional analysis within a randomly selected subcohort of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Germany comprising 2134 middle-aged men and women. The Human FGF23 (C-Terminal) ELISA kit was used to measure FGF23 in citrate plasma. Dietary data were obtained at baseline via validated food frequency questionnaires including up to 148 food items. Results: Multivariable adjusted logistic regression showed that men had a 66% lower and smokers a 64% higher probability of having higher FGF23 (≥ 90 RU/mL) levels compared, respectively, with women and nonsmokers. Each doubling in parathyroid hormone, creatinine, and C-reactive protein was related to higher FGF23. Among the dietary factors, each doubling in calcium and total energy intake was related, respectively, to a 1.75 and to a 4.41 fold increased probability of having higher FGF23. Finally, each doubling in the intake of iron was related to an 82% lower probability of having higher FGF23 levels. Results did not substantially change after exclusion of participants with lower kidney function. Conclusions: In middle-aged men and women traditional and non-traditional CVD risk factors were related to higher FGF23 concentrations. These findings may contribute to the understanding of the potential mechanisms linking increased FGF23 to increased CVD risk.


Related Articles

  • Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis. Zaritsky, Joshua; Rastogi, Anjay; Fischmann, George; Yan, Jieshi; Kleinman, Kenneth; Chow, Georgina; Gales, Barbara; Salusky, Isidro B.; Wesseling-Perry, Katherine // Nephrology Dialysis Transplantation;Feb2014, Vol. 29 Issue 2, p437 

    Background The utilization of short-term daily hemodialysis has increased over the last few years, but little is known on its effects on the control of serum phosphate and fibroblast growth factor 23 (FGF23) levels. Methods We therefore performed a cross-sectional study to compare FGF23 levels...

  • Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia. Seiji Fukumoto // Endocrinology & Metabolism;Jun2014, Vol. 29 Issue 2, p136 

    Fibroblast growth factor 23 (FGF23) is a hormone that is produced by osteocytes and regulates phosphate and vitamin D metabolism through binding to the Klotho-FGF receptor complex. Excessive actions of FGF23 cause several kinds of hypophosphatemic rickets/osteomalacia. Tumor-induced...

  • Where is the link between mineral bone markers and cardiovascular disease in CKD? Cozzolino, Mario; Pasquali, Marzia // Clinical Kidney Journal;Dec2015, Vol. 8 Issue 6, p729 

    The article discusses the research on the use medical screening technique such as fibroblast growth factor 23 in detecting cardiovascular disease among chronic kidney disease patients and also mentions other diagnostic techniques such as Klotho and vitamin D.

  • Plasma Lipids and Betaine Are Related in an Acute Coronary Syndrome Cohort. Lever, Michael; George, Peter M.; Atkinson, Wendy; Molyneux, Sarah L.; Elmslie, Jane L.; Slow, Sandy; Richards, A. Mark; Chambers, Stephen T. // PLoS ONE;2011, Vol. 6 Issue 7, p1 

    Background: Low plasma betaine has been associated with unfavorable plasma lipid profiles and cardiovascular risk. In some studies raised plasma betaine after supplementation is associated with elevations in plasma lipids. We aimed to measure the relationships between plasma and urine betaine...

  • Hypertensive patients' perceptions of their physicians' knowledge about them: a cross-sectional study in Japan. Inoue, Machiko; Inoue, Kazuo; Matsumura, Shinji // BMC Family Practice;2010, Vol. 11, p56 

    Background: In order to evaluate the difference in quality of primary care provided by physicians between the types of medical institutions in Japan, we examined whether the physicians' comprehensive knowledge of their patients is perceived differently by the patients seen at clinics and...

  • DIALYSIS. PATHOPHYSIOLOGY AND CLINICAL STUDIES.  // Nephrology Dialysis Transplantation;May2014, Vol. 29 Issue suppl_3, piii501 

    No abstract available.

  • Regulation of renal phosphate handling: inter-organ communication in health and disease. Tatsumi, Sawako; Miyagawa, Atsumi; Kaneko, Ichiro; Shiozaki, Yuji; Segawa, Hiroko; Miyamoto, Ken-ichi // Journal of Bone & Mineral Metabolism;Jan2016, Vol. 34 Issue 1, p1 

    In this review, we focus on the interconnection of inorganic phosphate (Pi) homeostasis in the network of the bone-kidney, parathyroid-kidney, intestine-kidney, and liver-kidney axes. Such a network of organ communication is important for body Pi homeostasis. Normalization of serum Pi levels is...

  • FGF-23: the rise of a novel cardiovascular risk marker in CKD. Heine, Gunnar H.; Seiler, Sarah; Fliser, Danilo // Nephrology Dialysis Transplantation;Aug2012, Vol. 27 Issue 8, p3072 

    Elevated plasma levels of the phosphaturic hormone fibroblast growth factor 23 (FGF-23) are a hallmark of chronic kidney disease (CKD)-mineral and bone disorder. FGF-23 allows serum phosphate levels within physiological limits to be maintained in progressive CKD until end-stage renal disease is...

  • Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Kirkpantur, Alper; Balci, Mustafa; Gurbuz, Oguz Alp; Afsar, Baris; Canbakan, Basol; Akdemir, Ramazan; Ayli, Mehmet Deniz // Nephrology Dialysis Transplantation;Apr2011, Vol. 26 Issue 4, p1346 

    Background. Fibroblast growth factor-23 (FGF-23) is a phosphorus-regulating substance. Circulating FGF-23 levels increase markedly in dialysis patients and are independently associated with increased risk of mortality. Given the fact that cardiovascular disease is the leading cause of death in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics